women (or neonates) undergoing cesarean delivery (CD), where the mean blood loss is twice that of a VD with the potential for increased bleeding from delayed hysterotomy closure. We performed a randomized trial to compare maternal blood loss with immediate cord clamping (ICC) versus delayed cord clamping (DCC) in term CD. STUDY DESIGN: Two-center, randomized clinical trial comparing maternal blood loss with ICC ( 15 sec after birth) versus DCC (60 sec after birth) in term CD (NCT03150641). Women undergoing scheduled CD of full term singleton gestations were eligible. Those with abnormal placentation, fetal anomalies, known fetal anemia, growth restriction with abnormal Dopplers, preeclampsia, significant maternal anemia, bleeding disorders, planned cord blood banking or refusal of blood products were excluded. Immediately before CD, women were randomized in a 1:1 ratio to ICC or DCC. The primary outcome was drop in maternal hemoglobin (Hgb) from pre-op to post-op day one. Secondary maternal outcomes included estimated blood loss, postpartum hemorrhage (>1000 mL), need for uterotonics and blood transfusion. Neonatal outcomes including Hgb at 24-72 hrs of life were assessed. Assuming a mean Hgb drop of 1.37 AE 0.87 g/dL, with a hypothesized effect size of a 0.9 g/dL (1.25 SD) difference in the primary outcome between groups and anticipating 20% crossover, the required sample size (two-tailed a¼0.05, b¼0
48 Effect of obesity on platelet inhibition in highrisk pregnant women treated with low dose aspirin The Ohio State University College of Medicine, Columbus, OH OBJECTIVE: Low dose aspirin (LDA) is used for preeclampsia (PE) prevention in high risk women, but the precise mechanism and optimal dose is not known. Evidence suggests that an imbalance in prostacyclin and thromboxane A 2 (TxA 2 ) plays a key role in PE. Aspirin (ASA) has a dose-dependent effect blocking production of TxA 2 , a potent stimulator of platelet aggregation (PA) and promoter of vasoconstriction. Incomplete inhibition of PA, designated aspirin resistance (AR), can be reduced by increasing the ASA dose. Evidence in the non-obstetric literature suggests AR may be more common among patients with a high body mass index (BMI). This study examines the impact of obesity on platelet responsiveness in high risk women treated with LDA. STUDY DESIGN: Secondary analysis of a prospective multi-centered study investigating the effect of LDA (60mg) administration in women at high risk of PE. Maternal serum TxB 2 (an indirect measure of TxA 2 ) levels were drawn at three time points: randomization, 24-28, and 34-38 weeks' gestation. Patients were included in the analysis if they had at least one TxB 2 level after randomization. Patients were stratified by BMI categories (<30, 30-39, !40) and treatment arm (LDA vs. placebo). Median TxB 2 levels were calculated at each time point as well as rates of complete TxB 2 inhibition (<0.01 ng/mL). A multivariate logistic regression was performed to generate odds ratios (OR) for complete TxB 2 inhibition by BMI category adjusting for race, high risk group at randomization & nulliparity. RESULTS: There were 1018 patients included in the analysis, 505 (49.6%) and 513 (50.4%) in the LDA & placebo groups respectively. Median TxB 2 levels were significantly increased in women with a BMI !40 in both the LDA & placebo groups; Fig. 1 . There were substantial decreases in TxB 2 levels among LDA treated women in all BMI categories, but rates of complete TxB 2 inhibition were lowest in patients with BMI !40 when compared to BMI <30 and 30-39; OBJECTIVE: Prolonged pushing in the second stage of labor is associated with increased maternal and neonatal morbidity. Using a dental support device (DSD) may increase the effectiveness of the Valsalva maneuver and, thus, decrease duration of pushing. This study determined if using a DSD reduces duration of pushing in patients with vaginal delivery. STUDY DESIGN: A randomized, controlled trial of nulliparous patients with singleton gestations at term, admitted for a planned vaginal birth was conducted from 2017-2018. Patients were randomized immediately prior to pushing to the DSD or control groups. DSD patients received a Laboraide Ò mouthpiece (a commercially available dental device made of soft plastic, 3 mm in thickness, which is inserted over the lower jaw with bite plates overlying the molar teeth) and were instructed to bite down on the DSD while pushing. RESULTS: Of the 338 participants recruited into the study, 167 were randomized to the DSD group with 161 (96%) delivering vaginally and 171 were randomized to the control group with 161 (94%) delivering vaginally. Among all patients, there was no difference in median pushing time in the DSD vs. control groups [46 min (IQR 23, 80) (Figure 1 ). Among patients who did not receive oxytocin, the DSD group had a shorter median pushing time compared to the control group [39 min (IQR 22, 69) v. 59 min (IQR 33,79) P¼ .05]. There were no differences in obstetric or neonatal outcomes in the groups. Sixty-five percent of patients used the DSD 100% of the time while pushing. Women in the DSD group reported the DSD was helpful and comfortable, and they would use it again. CONCLUSION: DSDs may be useful in reducing the duration of the second stage of labor in women with spontaneous contractions.
